Key Points
- SVP Rhonda Farnum sold 31,067 shares on Dec. 3 at an average price of $18.75 for about $582,506, leaving her with 277,695 shares (a 10.06% reduction in her position).
- Recent quarter beat expectations: Theravance reported $0.07 EPS (vs. a -$0.03 consensus) and $19.99 million in revenue for the quarter.
- Market and analyst context: TBPH has a market cap of ~$939.9M, a P/E of 32.54, a 1‑year range of $7.90–$20.33, and an average analyst price target of $27.80 with a consensus rating of "Buy."
Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 31,067 shares of the firm's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total transaction of $582,506.25. Following the transaction, the senior vice president owned 277,695 shares in the company, valued at $5,206,781.25. This represents a 10.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Theravance Biopharma Price Performance
TBPH opened at $18.55 on Friday. The company has a market capitalization of $939.93 million, a price-to-earnings ratio of 32.54 and a beta of 0.14. Theravance Biopharma, Inc. has a 1-year low of $7.90 and a 1-year high of $20.33. The business has a 50 day moving average price of $16.00 and a two-hundred day moving average price of $13.30.
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.10. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%.The company had revenue of $19.99 million for the quarter, compared to analysts' expectations of $19.89 million. Equities analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.
Hedge Funds Weigh In On Theravance Biopharma
A number of institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC lifted its stake in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after buying an additional 781 shares in the last quarter. Creative Planning raised its holdings in shares of Theravance Biopharma by 6.7% during the third quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company's stock valued at $196,000 after acquiring an additional 842 shares during the period. State of Wyoming lifted its position in shares of Theravance Biopharma by 5.7% in the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company's stock valued at $209,000 after acquiring an additional 1,019 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Theravance Biopharma by 6.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company's stock valued at $174,000 after acquiring an additional 1,020 shares in the last quarter. Finally, Ballentine Partners LLC boosted its stake in Theravance Biopharma by 9.3% in the 2nd quarter. Ballentine Partners LLC now owns 14,315 shares of the biopharmaceutical company's stock worth $158,000 after purchasing an additional 1,221 shares during the period. Hedge funds and other institutional investors own 99.10% of the company's stock.
Analysts Set New Price Targets
TBPH has been the topic of a number of research analyst reports. Zacks Research lowered Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a report on Monday, September 15th. B. Riley began coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They set a "buy" rating and a $28.00 price objective for the company. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Theravance Biopharma in a research note on Wednesday, October 8th. Oppenheimer initiated coverage on shares of Theravance Biopharma in a report on Wednesday. They issued an "outperform" rating and a $27.00 target price on the stock. Finally, HC Wainwright raised their target price on shares of Theravance Biopharma from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Tuesday, November 11th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $27.80.
Check Out Our Latest Stock Report on Theravance Biopharma
About Theravance Biopharma
(
Get Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
